Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.

Novo Nordisk has lowered the monthly price of Wegovy (semaglutide) to $499 for cash-paying patients without insurance — a 23% reduction from $650 — effective immediately.

Novo said its discounted Wegovy would be available in pens of all dosage strengths to uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines through its NovoCare Pharmacy program.

Novo Nordisk launches direct-to-consumer marketing for its weight loss drug Wegovy. Patients will now be able to get home shipments of the drug for just $499 per month. The discount compares to the prior price of $1,349 per month in the U.S.

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The drugmaker also is making larger doses available for $499 through its self-pay program. Novo said the new pricing is available to both the uninsured and people who have insurance that doesn't cover the weight-loss drugs.